Pharmaceutical Manufacturing (ME8005 Part 1) Notes

Learning objectives

  • Describe the activities of manufacturing of pharmaceuticals
  • Describe the activities of manufacturing of medical devices

Overview: Manufacturing in Biomedical Sciences (BMS)

  • Topic: Manufacturing in BMS with a focus on pharmaceutical manufacturing; Part 1 of the module ME8005
  • Presented by Ong Fook Rhu, Singapore Polytechnic, School of Mechanical & Aeronautical Engineering

Contents (as per transcript)

  • Pharmaceutical Manufacturing
  • Manufacturing of Medical Devices

Part 1: Pharmaceutical Manufacturing

The production pipeline: three main stages

  • Industrial processes can be broken down into three main stages:
    • Research and Development (R&D)
    • Conversion of organic and natural substances into bulk pharmaceutical ingredients (BPIs) through chemical synthesis or fermentation, and extraction
    • Formulation of the final/finished pharmaceutical product
  • This sequence encapsulates the lifecycle from concept to formulated product

Categorisation of pharmaceutical manufacturing

  • The pharmaceutical manufacturing sector is categorized into two main streams:
    • Primary or API (Active Pharmaceutical Ingredient) Manufacturing
    • Secondary or Dosage/Finished Product Manufacturing
  • API vs Drug Product represents the core distinction between bulk active substances and finished, consumable dosage forms

Key terms: API, Drug Product, and related materials

  • API (Active Pharmaceutical Ingredient): the substance intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect body structure/function
  • Drug Product: the finished dosage form that contains the API and excipients, prepared for administration
  • Basic Chemicals and Different Raw Materials: inputs used to manufacture APIs and drug products
  • Process Characteristics: the nature of processes, facilities, and equipment required to produce APIs vs Drug Products
  • API vs Drug Product: Chemical & Biological Processing (synthesis, fermentation, extraction, purification) vs Physical Processing (granulating, dissolving, mixing, compressing)

Pharmaceutical manufacturing process characteristics

  • Distinct facilities, equipment, and processes are used for API manufacturing versus Drug Product manufacturing
  • API processes typically involve chemical & biological processing (synthesis, fermentation, extraction, purification)
  • Drug Product processes are primarily physical processing (granulating, dissolving, mixing, compressing)

What is an Active Pharmaceutical Ingredient (API)?: essential definitions

  • INTENDED USE clause: Any substance or mixture intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product
  • PHARMACOLOGICAL ACTIVITY clause: Substances intended to furnish pharmacological activity or direct effect in diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or function of the body

Bulk pharmaceutical substances (API): general characteristics

  • Typically consist of structurally complex organic compounds
  • Manufactured via a series of intermediate steps and reactions under precise conditions

API intermediates

  • An intermediate is a material produced during API processing that undergoes further molecular change or purification before becoming the API
  • Intermediates may or may not be isolated
  • Intermediates can be transported in liquid form or in dried, stable powder form

API manufacturing: plant structure and campaigns

  • API or Intermediate manufacturing facilities often operate as Multi-Product Bulk Manufacturing Plants (MPP)
  • Mostly utilize batch processes
  • Production occurs in scheduled ‘campaigns’ with durations ranging from a few days to several months until projected sales demand is met
  • The number of batches per campaign depends on market demand and API types

API manufacturing: methods available

  • APIs can be manufactured by:
    • Chemical Synthesis
    • Fermentation
    • Isolation/Recovery from natural products
    • Recombinant DNA
    • A combination of these processes

Types of products manufactured through different processes (examples)

  • Chemical Synthesis
  • Natural Product Extraction
  • Fermentation
  • Recombinant DNA
  • Antibiotics
  • Antineoplastic Agents
  • Vaccines
  • Antihistamines
  • Enzymes & Digestive Aids
  • Hormones (including Insulin)
  • CNS Depressants
  • Vitamins
  • Monoclonal Antibodies
  • Gene Therapy components
  • Hormones and Vaccines
  • Central Nervous System (CNS) Stimulants
  • HIV, cardiovascular, hematological agents, etc. (examples listed in slide: e.g., Proteins like Interferon; Gene therapy components; Hormones; Vitamins; CNS depressants; Insulin; Steroids; Monoclonal antibodies; Vaccines)

Chemical Synthesis: overview and process steps

  • Most common method for manufacturing APIs; generally a batch process
  • Involves a complex series of processes across stages:
    • Reaction
    • Separation
    • Crystallisation
    • Purification
    • Drying
  • Separation mechanisms (applied to remove impurities):
    • Extraction: separates liquid mixtures based on solubility differences
    • Decanting: pours off liquid, leaving insoluble solids settled
    • Centrifugation: uses centrifugal force to separate solids from liquids
    • Filtration: uses a porous barrier to separate mixtures

Reaction vessels and equipment (Chemical Synthesis)

  • Reactors: capacity ranges from 5050 to a few thousand gallons
  • Constructed from stainless steel or glass-lined carbon steel
  • Liquid materials are charged by pumping or vacuum; solids may be charged manually or via vacuum
  • Monitoring needed for temperature, pressure, and degree of mixing to achieve desired product and worker safety

Batch reactor setup and operation (illustrative features)

  • Typical configuration includes a reaction vessel, agitators, jacketed cooling/heating, pressure relief, condensers, and solvent/raw material addition lines
  • Safety and control systems monitor reaction parameters throughout the batch

Separation and purification: details

  • Separation mechanisms may be employed jointly or in multiple stages
  • Purification may require additional steps (often recrystallisation and/or solvent washing)
  • Crystallisation, purification, and drying are sequential steps in isolating the API
  • Drying is the final step in chemical synthesis to remove residual solvents; commonly uses tray, rotary, drum, tumble, or pressure filter dryers
  • Common drying equipment types include tumble dryers and combination filter/dryers
  • Example visuals: treadmill-like layout of dryers and reactors (described in slide images)
  • Video resource: https://youtu.be/BwTeFRcPeJI (How medicines are made – AstraZeneca)

Crystallisation: core concept

  • One of the most common separation techniques; can be used alone or with other separations
  • Crystals form from supersaturated solutions via cooling, evaporation, or adding a third component
  • Separation of crystals from solution achieved by centrifugation or filtration

Purification: core concept

  • May be needed after separation of the API or intermediate
  • Requires an appropriate number of steps
  • Often achieved via recrystallisation; also via washing with solvents and filtration

Drying: core concept

  • Final step to remove solvents from solids
  • Methods include tray, rotary, drum, tumble, or pressure filter dryers
  • Often implemented with tumble dryers; example equipment shown and video resource cited earlier

Extraction of natural and biological products (overview)

  • API raw materials can be sourced from animal tissue, plant tissue, roots, plasma
  • Process involves mixing with water and organic solvents (e.g., methylene chloride, chloroform, alcohol, toluene)
  • Provides isolation of the active ingredient from natural sources; yields are typically small relative to starting material; process is expensive
  • Remains mechanised with assembly-line processing due to volume reduction
  • Involves precipitation, purification, and solvent extraction for API recovery

API recovery and solvent management

  • Precipitation: change in solubility used to recover API from plant/animal tissues
  • Solvents help remove fats and oils while preserving API
  • Ammonia usage in extraction stages: used to control pH and prevent unwanted precipitation due to salt solubility; ammonia does not react with tissues

Fermentation: overview

  • Considered traditional biotechnology; API is a by-product of metabolism by microorganisms (bacteria, yeast, or fungi)
  • Microorganisms inoculated in a conducive liquid broth environment for rapid growth
  • Three main steps: inoculum/seed preparation, fermentation, product recovery
  • Process and outcomes can vary from hours to weeks; isolation of API occurs after fermentation via separation and purification
  • Inoculum and seed preparation stages include laboratory-scale seed cultures; contaminated seed tanks require sterilisation and re-inoculation

Fermentation: process details (broth-based)

  • Inoculum is charged into a sterilised fermenter; fermenter is agitated and aerated
  • Parameters monitored: pH, temperature, dissolved oxygen
  • Post-fermentation: broth is filtered or centrifuged to remove solids; API not yet isolated at this stage

Fermentation: recovery methods

  • Three methods commonly used: solvent extraction, direct precipitation, and ion exchange/adsorption
  • Dissolve the broth with solvents to recover the API via crystallisation
  • Precipitating agents (e.g., Cu, Zn) induce metal salt precipitation from broth, then solids are filtered
  • Ion exchange resin is used to adsorb API, which is later crystallised after dissolution or washing with acid/base solutions

Modern biotechnology & Recombinant DNA: concept and workflow

  • The product is produced by living cells using complex manufacturing processes
  • Cells (bacteria, yeast, or mammalian) are genetically engineered by introducing desired genes (recombinant DNA)
  • Stages include: genetic engineering of cells, fermentation, and product recovery
  • Purification typically uses chromatography; final crystallisation may be needed
  • The active ingredient is provided in vials or prefilled syringes, solution, or lyophilised form for stability
  • Lyophilisation (freeze-drying) increases shelf-life for solutions that degrade in liquid form
  • Notable notes and video references: Roche biotechnology production video (link in slide), and Amgen/FDA guidance references in the source

Biologics and recombinant DNA: production realities

  • Biologics are made by living cells using complex manufacturing processes
  • Stages include: cell culture, scale-up, product recovery and purification, quality assurance, fill and finish, and storage
  • Quality assurance includes identity, strength, quality, potency, and purity testing; strict environmental controls for storage and transport are required

Examples and visuals from recombinant DNA slides

  • Stage diagrams illustrate: creation of recombinant factors (e.g., Factor IX), scale-up in bioreactors, purification through filtration, chromatography, and crystallisation, and final formulation
  • Examples include BeneFIX (recombinant Factor IX) production steps and nanofiltration for safety
  • Diagrams also show: engineering of cells (e.g., insulin production in bacterial/human cells) and the concept of recombinant plasmids and bacterial clones

Stage summaries: recombinant DNA production flow

  • Stage 1: Creating recombinant production cells (isolate human gene, insert into production cell, stabilize/storage)
  • Stage 2: Producing the product in a bioreactor and performing downstream purification (filtration, chromatography, crystallisation)
  • Final products may be supplied as vials, syringes, or lyophilised powders with appropriate quality controls

Biologics manufacturing: lifecycle and scale-up

  • Cell Culture: thawing cells from working cell banks, initiating culture in bioreactors
  • Scale-Up: production in progressively larger vessels up to 10,000–20,000 L
  • Product Recovery and Purification: protein extraction and purification via chromatography; final polishing steps
  • Quality Assurance: identity, potency, strength, purity testing
  • Fill and Finish: packaging in appropriate formats with controlled environmental conditions for storage and transport

Secondary Pharmaceutical Manufacturing (finishing steps)

Overview and objectives

  • Produce finished drug or medicine in a usable form
  • Key processes: formulation, mixing and granulation, packaging (tableting and encapsulation)
  • Batch production using campaign regimen; dosage forms include tablets, capsules, liquids, creams/ointments, aerosols, patches, and injectables
  • Video reference: https://youtu.be/_LzCUhxdtyY (Gien pharmaceutical production site)

Tablet manufacturing: core concepts

  • Tablets account for the majority of oral solid medications
  • Tablets can be compressed or molded and may be coated
  • Production involves combining API with fillers (sugars, starch), binders (corn syrup, starch)
  • Direct compression, wet granulation, or dry granulation are common methods
  • QC-passed tablets may be packaged directly

Tablet manufacturing: equipment and steps

  • Common processing steps include milling (mill), blending, granulation (wet or dry), drying, compression, coating (optional), and dissolution testing
  • Tablet presses and coating equipment are used; photos illustrate die and punch configurations, weight control, and compression steps
  • Optional feeders for additional ingredients (lubricants) and excipients may be used in the process

Tablet processing technologies

  • Direct Compression: tablets formed without significant modification of materials
  • Wet Granulation: API + filler wetted, binder added to form granules, granules blended with lubricants and compressed
  • Dry Granulation (Slugging): used for moisture/temperature-sensitive ingredients or those with high binding properties; involves weighing, slugging, dry screening, lubrication, and compression
  • Overview of equipment: mill, tablet press, coater

Tablet engineering and tooling (illustrative)

  • Tablet press components include upper/lower punches, dies, fill cam, and compression rolls; ejection and precompression stages are shown in diagrams
  • Weight control units ensure consistent tablet masses

Tablet coating and why it is used

  • Coating purposes include moisture, oxygen, or light protection; taste masking; appearance differentiation; and enteric coating for delayed release
  • Process typically performed in a rotary drum or by spraying; coated tablets may be polished in a secondary drum and then stamped with identifying information via rotary ink press

Capsule manufacturing: soft vs hard shells

  • Capsules are commonly used as the next solid oral dosage form after tablets
  • Soft capsules contain injected liquid, paste, or powder; soft gelatin capsules come in various sizes and shapes (round, oval, oblong, tube)
  • Hard capsules are filled with powdered material containing API

Capsule filling: typical process steps (illustrative sequence)

  • Powder dosing and vacuum isolation
  • Powder compression and vacuum discharge
  • Ejection and plug recovery
  • Capsule filling and plug recovery (illustrative steps often shown in process diagrams)

Liquid dosage forms: overview

  • Weighted ingredients are dissolved in a suitable liquid, then mixed in vessels and stored in tanks before final packaging
  • Preservatives may be added to prevent mold and bacterial growth
  • Sterilisation is performed for liquids intended for injection or ophthalmic use

Ointments and creams: formulation notes

  • Ointments: typically blends of API with petroleum derivatives or wax-based bases; the mixture is cooled, rolled, and dispensed into tubes
  • Creams: semi-solid emulsions (oil-in-water or water-in-oil) formed by emulsifying phases with heating, followed by vigorous mixing

Final note: end of Part 1

  • The document ends Part 1 with the end of the pharmaceutical manufacturing content; no explicit content on medical devices is provided in the slides presented

Connections to broader themes and implications

  • The three-stage pharmaceutical manufacturing model aligns with Good Manufacturing Practice (GMP) expectations, quality-by-design, and regulatory oversight, ensuring product safety, efficacy, and consistent quality
  • The API-focused sections emphasize the importance of material science, unit operation knowledge, and scale-up challenges when moving from bench to production
  • Biotechnology and recombinant DNA sections highlight the shift toward biologics and cell-based therapies, with added considerations for cold chain, lyophilisation, and advanced purification (chromatography) techniques
  • The secondary manufacturing sections demonstrate the translation of bulk APIs into consumer-ready dosage forms, requiring robust process engineering, QC testing, and regulatory compliance for each dosage form

References, videos, and additional resources mentioned in the slides

  • How medicines are made – AstraZeneca video: https://youtu.be/BwTeFRcPeJI
  • Phases of recombinant DNA production and biotech processes: various slides and figures throughout the document
  • YouTube references for bioprocessing (fermentation, separation/recovery, purification) listed in the slides: links provided in the transcript (e.g., Bioprocessing Part 1–3)
  • Video on pharmaceutical production site (Gien): https://youtu.be/_LzCUhxdtyY